TR201910330T4 - Anti-fosfolin d4 antikoru içeren ilaç. - Google Patents
Anti-fosfolin d4 antikoru içeren ilaç. Download PDFInfo
- Publication number
- TR201910330T4 TR201910330T4 TR2019/10330T TR201910330T TR201910330T4 TR 201910330 T4 TR201910330 T4 TR 201910330T4 TR 2019/10330 T TR2019/10330 T TR 2019/10330T TR 201910330 T TR201910330 T TR 201910330T TR 201910330 T4 TR201910330 T4 TR 201910330T4
- Authority
- TR
- Turkey
- Prior art keywords
- present application
- antibody
- phospholine
- pdl4
- phospholipase
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229960002017 echothiophate Drugs 0.000 title 1
- 102100036183 5'-3' exonuclease PLD4 Human genes 0.000 abstract 2
- 101710142129 5'-3' exonuclease PLD4 Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Mevcut başvuru, fosfolipaz D4'e (PDL4) bağlanan antikorları içeren ilaçlar aynı zamanda söz konusu ilaçları aktive edilmiş B hücreleri tespit etmek ve baskılamak için kullanan bir yöntem sağlamaktadır. Mevcut başvuru ayrıca aktif önleyici fonksiyondan kaynaklanan alerjilerin ve otoimmün hastalıkların terapisine yöneliktir. Bu problemleri çözmek için mevcut başvuru bir aktif bileşen olarak fosfolipaz D4'ün (PDL4) ekstraselüler alanına bağlanan bir monoklonal antikor ve bunun bir antijen bağlama bölgesini içeren bir fragmanını sağlamaktadır.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013158258 | 2013-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201910330T4 true TR201910330T4 (tr) | 2019-07-22 |
Family
ID=51493000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/10330T TR201910330T4 (tr) | 2013-07-30 | 2014-07-30 | Anti-fosfolin d4 antikoru içeren ilaç. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20160168266A1 (tr) |
EP (1) | EP3027656B1 (tr) |
JP (3) | JP6431523B2 (tr) |
KR (1) | KR102367760B1 (tr) |
CN (1) | CN105745226B (tr) |
AU (1) | AU2014297217B2 (tr) |
BR (1) | BR112016002001B1 (tr) |
CA (1) | CA2919736C (tr) |
DK (1) | DK3027656T3 (tr) |
ES (1) | ES2736324T3 (tr) |
HU (1) | HUE044469T2 (tr) |
MX (1) | MX2016001193A (tr) |
PL (1) | PL3027656T3 (tr) |
RU (1) | RU2709741C2 (tr) |
SG (2) | SG11201600666SA (tr) |
TR (1) | TR201910330T4 (tr) |
WO (1) | WO2015016386A1 (tr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3431504T3 (da) * | 2012-01-31 | 2021-06-28 | Sbi Biotech Co Ltd | Antiphospholipase d4-antistof |
MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
JP7140367B2 (ja) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | ヒト由来サンプルにおける可溶型tlr7の分析 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO118524B1 (ro) * | 1992-11-13 | 2003-06-30 | Idec Pharmaceuticals Corp San | Metoda pentru tratarea unei tulburari legata de celulele b |
AU5784799A (en) * | 1998-08-24 | 2000-03-14 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
US20020146686A1 (en) * | 2000-12-07 | 2002-10-10 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
JP2013052781A (ja) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | 車両用ミラー装置 |
DK3431504T3 (da) * | 2012-01-31 | 2021-06-28 | Sbi Biotech Co Ltd | Antiphospholipase d4-antistof |
-
2014
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/ja active Active
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/tr unknown
- 2014-07-30 PL PL14761423T patent/PL3027656T3/pl unknown
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/hu unknown
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en active Application Filing
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/zh active Active
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/pt active IP Right Grant
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/da active
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/ko active IP Right Grant
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
- 2014-07-30 MX MX2016001193A patent/MX2016001193A/es unknown
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/ru active
- 2014-07-30 ES ES14761423T patent/ES2736324T3/es active Active
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/ja not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/ja active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112016002001B1 (pt) | 2023-04-25 |
JP6843449B2 (ja) | 2021-03-17 |
MX2016001193A (es) | 2016-05-26 |
AU2014297217A1 (en) | 2016-02-18 |
DK3027656T3 (da) | 2019-08-05 |
JP2019014759A (ja) | 2019-01-31 |
SG11201600666SA (en) | 2016-02-26 |
EP3027656B1 (en) | 2019-06-26 |
ES2736324T3 (es) | 2019-12-27 |
CN105745226B (zh) | 2020-03-06 |
WO2015016386A1 (en) | 2015-02-05 |
PL3027656T3 (pl) | 2019-10-31 |
HUE044469T2 (hu) | 2019-10-28 |
KR20160034934A (ko) | 2016-03-30 |
CN105745226A (zh) | 2016-07-06 |
US20160168266A1 (en) | 2016-06-16 |
CA2919736C (en) | 2022-03-22 |
RU2016106708A (ru) | 2017-09-01 |
AU2014297217B2 (en) | 2020-01-16 |
RU2709741C2 (ru) | 2019-12-19 |
RU2016106708A3 (tr) | 2018-03-30 |
JP6431523B2 (ja) | 2018-11-28 |
KR102367760B1 (ko) | 2022-02-24 |
CA2919736A1 (en) | 2015-02-05 |
US20210130493A1 (en) | 2021-05-06 |
SG10201800592SA (en) | 2018-03-28 |
JP2019214621A (ja) | 2019-12-19 |
EP3027656A1 (en) | 2016-06-08 |
JP2016534022A (ja) | 2016-11-04 |
BR112016002001A2 (pt) | 2017-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
CR20140146A (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
EA201792451A1 (ru) | Антитела к ox40 и способы их применения | |
EA201501063A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
EA201592203A1 (ru) | Способы лечения таупатии | |
UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
NZ631543A (en) | Antibodies to bradykinin b1 receptor ligands | |
EA201690032A1 (ru) | Антитела к лектиноподобному рецептору 1 окисленных липопротеинов низкой плотности и способы применения | |
TR201819828T4 (tr) | Anti-fosfolipaz d4 antikoru. | |
EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
EA201590918A1 (ru) | Антитела к bmp-6 | |
IN2014DN09717A (tr) | ||
TR201910330T4 (tr) | Anti-fosfolin d4 antikoru içeren ilaç. | |
BR112013005423A2 (pt) | composições de anticorpo anti-vegfr-3. | |
GB201207155D0 (en) | Antibodies |